A Phase 1 Open-Label, Parallel-Group, Adaptive, Single-Dose Study to Evaluate the Pharmacokinetics and Pharmacodynamics of GS-9674 in Subjects With Normal and Impaired Hepatic Function
Phase of Trial: Phase I
Latest Information Update: 31 Aug 2017
At a glance
- Drugs GS 9674 (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Pharmacokinetics
- Sponsors Gilead Sciences
- 25 Aug 2017 Planned End Date changed from 1 Sep 2017 to 1 Mar 2018.
- 25 Aug 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Mar 2018.
- 10 Jun 2017 Biomarkers information updated